Tag: interstitial lung disease
-
Actemra Side Effects: Pulmonary Hypertension, Interstitial Lung Disease, Pulmonary Alveolar Proteinosis
FDA Watch List Includes Actemra: Evaluating Regulatory Action Based On Possible Signs Of Serious Risk, New Safety Information (Posted by Tom Lamb at DrugInjuryWatch.com) In July 2018 the FDA issued this document,…
-
2018 Emerging Drug Litigations: Viberzi and Actemra
Additional information concerning the potentially harmful side effects of Viberzi and Actemra was released over the course of 2017, and we will continue to monitor the situation in 2018.
-
Multiple Myeloma Drug Pomalyst Associated With Side Effects Risks Of Cardiac Failure, Interstitial Lung Disease, And Hepatotoxicity
In May 2015 The Medicines and Healthcare Products Regulatory Agency In UK Issued A Drug Safety Update; Will There Be Similar FDA Action? (Posted by Tom Lamb at DrugInjuryWatch.com) Pomalidomide (brand name:…
-
Multaq: Increased Risks Of Side Effects, Including Death, Outweigh Any Benefits Say Researchers Who Reviewed Clinical Data
In Addition, They Are Highly Critical Of Relationship The Sanofi Aventis Drug Company Had With Those Doctors Who Developed Prescribing Guidelines (Posted by Tom Lamb at DrugInjuryWatch.com)As we know, now, since being approved by the FDA…
-
Multaq Associated Lung Disease And Pulmonary Toxicity Pointed Out By New Safety Warnings In September 2012 Revised Label
Heart Drug Multaq Can Cause Pulmonary Fibrosis And Pneumonitis; Symptoms Are Inflammation Of The Lungs, Including Scarring And Thickening (Posted by Tom Lamb at DrugInjuryWatch.com) Multaq (dronedarone) is a drug used to treat abnormal heart rhythm (atrial…
-
Zocor Label Change: Interstitial Lung Disease (ILD) Added As Possible Adverse Reaction
November 2010 FDA Approval Of Merck Action Raises Profile Of This Emerging Drug Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) As we reported recently, the October 2010 issue of the Canadian Adverse Reaction…
-
June 2010 Update On Several Possible Zocor (Simvastatin) Side Effects
From Myopathy And Rhabdomyolysis To Tendon Ruptures And Interstitial Lung Disease (Posted by Tom Lamb at DrugInjuryWatch.com) _________________________________________________________________________________________ UPDATE: FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce…